A feasibility study of the use of peg-filgrastim as primary prophyraxis for FOLFIRINOX therapy for unresectable pancreatic cancer
Phase 2
- Conditions
- unresectable pancreatic cancer
- Registration Number
- JPRN-UMIN000016595
- Lead Sponsor
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are excluded if they have received prior chemotherapy or radiation therapy ( except for adjuvant chemotherapy); UGT genetic polymorphisms of homozygous UGT1A1*28 or UGT1A1*6 or heterozygous UTG1A1*6 and UGT1A1*28; diarrrhea including water stools; active infection or other serious concomitant diseases.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method relative dose indensity
- Secondary Outcome Measures
Name Time Method neutropenia, febrile neutropenia, other adverse events(anemia, thrombocytopenia, anorexia, nausea, vommiting, diarrhea, peripheral sensory neuropathy), treatment cycles